Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Yungjin Pharmaceutical Co., Ltd.

Korea Institute of Oriental Medicine

Sei Ryang Oh

Kyung Seop Ahn

Hyeong Kyu Lee

Doo Young Kim

Jung Hee Kim

Ok-Kyoung Kwon

Joong Ku Lee

Jae Wha Kim

Ok Kyoung Kwon

Ho Bum Kang

Mi Jin Kim

Hyung Won Ryu

In Sik Shin

Hyouk Joung

Gui Hua Quan

Bo Young Park

Sang Ku Lee

Sang Ho Choi

Sang Woo Lee

Seung Hyung Kim

Hyuk Hwan Song

Semi Kim

Ki-Young Sohn

Byung-hwan Ryoo

Dae-hee Shin

Ji-seok Yoo

Yongnam Lee

Joo Heon Kim

Jong Koo Kang

Jae Sung Song

Soon Ja Choi

Hang Jin

Tae Suk Lee

Wan Yi Li

Da Jung Ji

SuUi Lee

Ha Young Jang

Kyoung-youl Lee

Mee-Young Lee

Hwa-Young Son

Ji Won Park

So Young Kim

Gyoon Hee Han

Hee Gu Lee

Young Sik Jung

Doo-Young Kim

Su Ui Lee

Hyun Woo Oh

Yong-Hae Han

Seung Ho Kim

Myung Hwan Kim

Beom Su Park

Joongku Lee

Dur Han Kwon

Jae Min Shin

Byung Sun Min

Mi Jin Jang

Jung Joo Hong

Soo Yong Kim

Goo Taeg Oh

Young Eun Ko

Jae Jong Go

Jang Mi Sun

Hye Suk Lee

Yoosik Yoon

Byoung Whui Choi

Jang Mi Son

Yi Hua Pei

Cheol Jung Lee

Khiev Piseth

Yong Yeon Cho

Li Wan Yi

Jae Hyoung Song

Gun Cheol Kim

Byeong Hwa Jeon

Hea Young Park

Gansukh Enkhtaivan

Da Chung Ji

Mun Ock Kim

Jin Hang

Hyun Jae Jang

Giselle Tomayo-Castillo

Ji Eun Yuk

Katia Rosales-Ovares

Mee Hyun Lee

Rodrigo Gamez-Lobo

Eun Ah Kim

Fifit Juniarti

Guang Hai Shen

Seong Kyu Park

Rifatul Widjhati

Woo Namkung

Jin Hyub Paik

Hui Seong Kim

Piseth Khiev

Byung-Hwan Ryoo

Ji-Seok Yoo

Gui Hua Natural Medicines Research Center Quan

The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, anextract, aextract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only anextract, aextract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of theextract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

Composition for preventing or treating obesity or diabetes, comprising acanthopanax senticosus extract and garcinia cambogia extract or compound isolated therefrom

The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising aextract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising aextract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising aextract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-&#x3b1;, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.

Pharmaceutical composition comprisingextract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (COPD)

The present invention relates to a composition for preventing or treating asthma comprising aJ. Poiss. ex Franch extract or a fraction thereof. TheJ. Poiss. ex Franch extract or the fraction thereof according to the present invention does not exhibit toxicity, inhibits the generation of NO, IL-4, IL-5, and IL-13 and the generation of reactive oxygen species in the bronchial tubes, and has significantly induced the alleviation of airway hyperresponsiveness, inhibition of the infiltration of inflammatory cells into the bronchial tubes, and reduction of inflammatory cells in bronchoalveolar lavage fluid in an ovalbumin-induced asthma mouse model. In addition, theJ. Poiss. ex Franch extract or the fraction thereof according to the present invention effectively inhibits the secretion of immunoglobulins in serum, secretion of mucus in the bronchial tubes, and infiltration of inflammatory cells into lung tissue and thus can be usefully used as a safe preparation for preventing and treating asthma.

Pharmaceutical composition for preventing or treating asthma comprisingJ. Poiss. ex Franch extract or fraction thereof

A composition comprising a purified extract isolated fromvar.containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Method of treating chronic obstructive pulmonary disease (CPD) with verproside

The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.

Antiviral composition containing material involved in phosphatidylcholine synthesis pathway

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Composition containing lignan compound as active ingredient for preventing or treating cancer

[object Object]

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases or asthma comprising aextract or a fraction thereof as an active ingredient, and a health functional food and a feed additive for preventing or improving inflammatory diseases or asthma comprising the extract or the fraction as an active ingredient.

Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient

The present invention relates to an injenane-type diterpene compound derived fromLiou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same

The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis

The present invention relates to a diterpene compound derived from, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same

The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and byextract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma

The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising theextract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. Theextract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, theextract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

Growing community of inventors

Daejeon, South Korea

Sei Ryang Oh